glp 1 agonists for type 2 diabetes Targeting GLP-1, GIP & GCG in Obesity and Research GLP-1 receptor agonists for individualized

In 2009, a second GLP-1 RA was approved liraglutide, which has to be injected once daily

Injection site reactions occur in 14% of users, typically presenting as mild redness, itching, or temporary discomfort at the injection location

Brown JC, Pederson RA, Jorpes E, Mutt V

With the dual effect of "diabetes" and "weight loss", the development of GLP-1 long-acting receptor agonists has become a research hotspot at home and abroad

Hughes S, Neumiller JJ

A more recent analysis using cardiovascular outcome trials further indicated no excess risk of either acute pancreatitis [Peto OR 0.89 (95% CI 0.63, 1.27)] or pancreatic cancer [Peto OR 0.84 (95% CI 0.53, 1.35)] with GLP-1RAs vs